Table 2.
CYP2B6 and CYP2C19 allele and genotype frequencies, and genotype based phenotypes of neuroblastoma patients (N = 50).
| Na | Frequency (%) | ||
|---|---|---|---|
| Neuroblastoma patients | Caucasian populationb | ||
| CYP genotype based phenotype estimation | |||
| CYP2B6 alleles | |||
| *4 | 5 | 5.0 | 2.2–6.2 |
| *5 | 11 | 11.0 | 9–12.2 |
| *6 | 22 | 22.0 | 7–28.1 |
| *9 | 0 | 0 | 0–4.4 |
| *22 | 1 | 1.0 | 1.4–2.4 |
| Poor/intermediate CYP2B6 metabolizer (N = 20) | |||
| CYP2B6 genotypes | |||
| *1/*6 | 14 | 28.0 | 22.1–22.9 |
| *6/*6 | 2 | 4.0 | 5.4–7.3 |
| *5/*6 | 2 | 4.0 | 5.3–7.3 |
| *4/*6 | 2 | 4.0 | < 2.1 |
| Normal/rapid CYP2B6 metabolizer (N = 30) | |||
| *1/*1 | 17 | 34.0 | 21–24.1 |
| *1/*5 | 9 | 18.0 | 7.3–11.3 |
| *1/*4 | 3 | 6.0 | 1–4 |
| *1/*22 | 1 | 2.0 | 1.3–2.1 |
| CYP2C19 allelesc | |||
| *2 | 15 | 15.3 | 6.0–15.0 |
| *3 | 0 | 0 | < 1 |
| *4 | 0 | 0 | < 1 |
| *17 | 20 | 20.4 | 21.5–25.0 |
| Poor/intermediate CYP2C19 metabolizer (N = 12) | |||
| CYP2C19 genotypesc | |||
| *1/*2 | 6 | 12.2 | 18.3–18.5 |
| *2/*2 | 3 | 6.1 | 2.1 |
| *2/*17 | 3 | 6.1 | 6.3 |
| Normal CYP2C19 metabolizer (N = 23) | |||
| *1/*1 | 23 | 46.9 | 39.0–40.5 |
| Rapid/ultrarapid CYP2C19 metabolizer (N = 14) | |||
| *1/*17 | 11 | 22.4 | 26.9–27.5 |
| *17/*17 | 3 | 6.1 | 4.6–4.7 |
anumber of alleles or number of patients. bBased on PharmVar (https://www.pharmgkb.org/page/cyp2b6RefMaterials, https://www.pharmgkb.org/page/cyp2c19RefMaterials), Zanger36, Ionova69, Zhou46. cMissing CYP2C19 data for 1 patient.